



## Primary Series (age 6 months and up)

Initial doses of COVID-19 vaccine administered to induce an immune response and provide initial protection.

### Non-Immunocompromised Individuals

**Age 6 months to 4 years:** Consists of 2 doses: Spikevax Bivalent (Moderna) OR Spikevax (Moderna) OR 3 doses: Comirnaty (Pfizer-BioNTech)

**Age 5 years and up:** Consists of 2 doses: Comirnaty Bivalent (Pfizer-BioNTech), Spikevax Bivalent (Moderna), Nuvaxovid (Novavax) or mixed series as appropriate for given age group.

**2nd or 3rd\* Primary Series Dose: Minimum 56 days (8 weeks) between primary series doses**

\* Applicable only to Comirnaty (Pfizer-BioNTech) for 6 months to 4 years of age

### Moderately to Severely Immunocompromised Individuals

Defined in: NS eligibility criteria (click [link](#) for details), immunosuppressive medication list (click [link](#) for details), and primary immunodeficiency list (click [link](#) for details). Immunizers verify individuals meet eligibility criteria prior to administration.

#### Age 6 months to 4 years:

**Option 1 (preferred): Three Spikevax Bivalent (Moderna) doses** (Spikevax Original can be used). 2nd Dose: Minimum 28 days (4 weeks) after 1st dose, 3rd Dose: Preferred 56 days (8 weeks) after 2nd dose.

**Option 2: Four Comirnaty (Pfizer-BioNTech) doses.** 2nd and 3rd Doses: Minimum 28 days (4 weeks) after 1st and 2nd dose, 4th Dose: Minimum 56 days (8 weeks) after 3rd dose.

#### Age 5 years and up:

Consists of 2 doses: Comirnaty Bivalent (Pfizer-BioNTech), Spikevax Bivalent (Moderna), Nuvaxovid (Novavax) or mixed series as appropriate for given age group.

PLUS

3rd Primary Series Dose

Administered to moderately to severely immunocompromised individuals who may not achieve adequate protection from a 2 dose primary series


It is recommended that the moderately to severely immunocompromised be immunized with a primary series with an mRNA COVID-19 vaccine authorized for their age

**2nd Primary Series Dose: Minimum 28 days (4 weeks) after 1st dose**

**3rd Primary Series Dose: Preferred 56 days (8 weeks) after 2nd dose**

Individuals who are moderately to severely immunocompromised may benefit more from a primary series with Spikevax Bivalent (Moderna) vaccine.

## COVID-19 Primary Series Vaccines (6 months and up)



### Special Considerations

- Individuals 6 months of age and older, COVID-19 vaccines may be given concurrently (i.e., same day), or at any time before or after, non-COVID-19 vaccines (including live and non-live vaccines)
- For 6 months to 4 years: the same mRNA COVID-19 vaccine product should be offered for the subsequent dose in a vaccine series started with a specific mRNA COVID-19 vaccine. If two different products are given, please refer to PHAC's resource: [Quick reference guide on the use of COVID-19 vaccines: Managing vaccine administration errors or deviations](#) for guidance.
- Specific intervals between COVID-19 infection and primary series vaccination are advised. See Table 4 in [link](#) for details.
- Nuvaxovid (Novavax) vaccine can be used in those 18 years of age and up for primary series and booster doses, in those not able or willing to receive mRNA vaccines. See Table 1 and 2 in [link](#) for details.

NS Health Vaccine Consult Service available by phone: 1-833-768-1151, email: [VaccineConsult@nshealth.ca](mailto:VaccineConsult@nshealth.ca), or fax: 1-902-425-6707 8:30am-4:30pm, 7 days/week




## Booster Doses (age 5 years and up)

*Administered to restore protection that may have decreased over time in individuals expected to have initially achieved an adequate response to their primary series*

As of June 30, 2023, everyone 5 years of age and older who completed their primary series is eligible to receive a single bivalent booster dose if they have not already received a booster dose. Individuals who have received one booster dose are not eligible for additional doses until the fall 2023 COVID-19 booster campaign to allow the minimum interval of 168 days between booster doses.

**Minimum number of days individuals can receive any booster dose is 168 days after their last COVID-19 vaccine AND 168 days after their last COVID-19 infection.**



### Special Considerations

- Individuals 6 months of age and older, COVID-19 vaccines may be given concurrently (i.e., same day), or at any time before or after, non-COVID-19 vaccines (including live and non-live vaccines)
- Specific intervals between COVID-19 infection and vaccination are advised. See Table 4 in [link](#) for details. Note-Minimum number of days any individual can receive a booster dose is 168 days after their last COVID-19 vaccine AND 168 days have passed since their last COVID-19 infection.
- Nuvaxovid (Novavax) vaccine can be used in those 18 years of age and up for primary series and booster doses, in those not able or willing to receive mRNA vaccines. See Table 1 and 2 in [link](#) for details.

NS Health Vaccine Consult Service available by phone: 1-833-768-1151,  
email: [VaccineConsult@nshealth.ca](mailto:VaccineConsult@nshealth.ca), or fax: 1-902-425-6707 8:30am-4:30pm, 7 days/week